-
Nicole Lamanna, MD; Columbia University Medical Center; 5Live #ASH20 Part 1
6:57
Key insights from the 2020 Annual Hematology meeting in Chronic Lymphocytic Leukemia
-
Nicole Lamanna, MD; Columbia University Medical Center; 5Live #ASH20 Part 2
4:23
Key insights from the 2020 Annual Hematology meeting in Chronic Lymphocytic Leukemia
-
Susan O'Brien, MD; University of California Irvine; 5Live #ASH20
5:12
Key insights from the 2020 Annual Hematology meeting in Chronic Lymphocytic Leukemia
-
Matthew Davids, MD, MMSc; Dana Farber Cancer Institute; 5Live #ASH20
6:38
Key insights from the 2020 Annual Hematology meeting in Chronic Lymphocytic Leukemia
-
The Expanding Role of BTK Inhibitors for the Treatment of Patients With Chronic Lymphocytic Leukemia (CLL)_Webcast_Matthew Davids, MD, MMSc
40:50
-
Othman Al-Sawaf, MD University Hospital, Cologne 5Live #ASCO20
3:48
Key Insights on Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial
-
Lindsey Roeker, MD Memorial Sloan-Kettering Cancer Center 5Live #ASCO20
3:55
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
-
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
